Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 26;25(Suppl C):C109-C111.
doi: 10.1093/eurheartjsupp/suad012. eCollection 2023 May.

Bempedoic acid: what prospective uses?

Ilaria Jacomelli  1 , Luca Monzo  1   2 , Germana Panattoni  1 , Chiara Lanzillo  1 , Marco Rebecchi  1 , Leonardo Calò  1
Affiliations

Bempedoic acid: what prospective uses?

Ilaria Jacomelli et al. Eur Heart J Suppl. .

Abstract

There is still the need to lower LDL-c, although the use of statins, ezetimibe and proprotein convertase subtilisin/kexin type 9. Patients with atherosclerotic cardiovascular disease and/or familial hypercholesterolaemia are treated with statins at maximum tolerated dose, with or without further lipid-lowering drugs, but very often, we can't reach the goal, so bempedoic acid treatment lead to a significant reduction in low-density lipoprotein cholesterol, in different groups of patients, with a favourable safety profile.

Keywords: Bempedoic acid; Cardiovascular disease; LDL-cholesterol; Statin intolerance.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

References

    1. Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith Cet al. . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–1681. - PMC - PubMed
    1. Catapano1 AL, Manu MC, Burden A, Ray KK, The SANTORINI Investigators . LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study. Eur Heart J 2022;43:ehac544–2373.
    1. De Luca L, Arca M, Temporelli PL, Meessen J, Riccio C, Bonomo Pet al. . Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry. Int J Cardiol 2020;316:229–235. - PubMed
    1. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru Get al. . EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol 2021;28:1279–1289. - PubMed
    1. Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RCet al. . Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 2016;7:13457. - PMC - PubMed